Mostrar el registro sencillo del ítem
dc.contributor.author | Bagan, José![]() |
es_ES |
dc.contributor.author | Martorell, Miguel![]() |
es_ES |
dc.contributor.author | Cebrián, Jose L.![]() |
es_ES |
dc.contributor.author | Rubert, Andrea![]() |
es_ES |
dc.contributor.author | Bagán, Leticia![]() |
es_ES |
dc.contributor.author | Mezquida, Carlos![]() |
es_ES |
dc.contributor.author | Hervás-Marín, David![]() |
es_ES |
dc.date.accessioned | 2023-11-28T19:02:15Z | |
dc.date.available | 2023-11-28T19:02:15Z | |
dc.date.issued | 2022-08 | es_ES |
dc.identifier.issn | 1432-6981 | es_ES |
dc.identifier.uri | http://hdl.handle.net/10251/200293 | |
dc.description.abstract | [EN] Objectives Our main purpose and research question were to analyze and quantify whether there were signifcant diferences in the time to develop cancer among patients with oral leukoplakia (OL), comparing the more susceptible cases to those with the least susceptibility to malignancy. Materials and methods We followed 224 cases of OL after surgical or CO2 laser treatment for a mean time of 6.4 years. A Bayesian mixture cure model based on the Weibull distribution was used to model the relationship between our variables and cancer risk. In this model type, the population is considered a mixture of individuals who are susceptible or non-susceptible to developing cancer. The statistical model estimates the probability of cure (incidence model) and then infers the time to malignancy. The model was adjusted using the R-package INLA using default priors. Results Histology type (moderate or severe dysplasia) and tongue location showed hazard ratios (HR) of 3.19 (95% CI [1.05¿8.59]) and 4.78 (95% CI [1.6¿16.61]), respectively. Both variables increased the risk of malignant transformation, thus identifying a susceptible subpopulation with reduced time required to develop cancer, as with non-homogeneous leukoplakias. The median time for cancer development was 4 years and 5 months, with a minimum of 9 months after the diagnosis of OL and a maximum of 15 years and 2 months. Conclusions Susceptible patients with non-homogeneous leukoplakia, dysplasia, or leukoplakia in the tongue develop cancer earlier than those with homogeneous OL and those without dysplasia. Clinical relevance The novel contribution of this research is that, until now, the time it took for oral leukoplakias to develop cancer based on whether they were homogeneous or non-homogeneous, and if they have or not epithelial dysplasia, had not been comparatively described and quantifed. As a fnal result, the time to malignant transformation in non-homogeneous and dysplastic leukoplakias is signifcantly shorter. | es_ES |
dc.description.sponsorship | Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This study has been funded by Instituto de Salud Carlos III (Spain) through the project "PI19/00790" (Cofunded by European Regional Development Fund/European Social Fund "A way to make Europe"/" Investing in your future"). Principal Investigator: Jose Bagan. | es_ES |
dc.language | Inglés | es_ES |
dc.publisher | Springer-Verlag | es_ES |
dc.relation.ispartof | Clinical Oral Investigations | es_ES |
dc.rights | Reconocimiento (by) | es_ES |
dc.subject | Oral leukoplakia | es_ES |
dc.subject | Malignancy | es_ES |
dc.subject | Evolution | es_ES |
dc.subject.classification | ESTADISTICA E INVESTIGACION OPERATIVA | es_ES |
dc.title | Effect of clinical and histologic features on time to malignancy in 224 cases of oral leukoplakia treated by surgery | es_ES |
dc.type | Artículo | es_ES |
dc.identifier.doi | 10.1007/s00784-022-04486-x | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ISCIII//PI19%2F00790/ | es_ES |
dc.rights.accessRights | Abierto | es_ES |
dc.contributor.affiliation | Universitat Politècnica de València. Escuela Politécnica Superior de Alcoy - Escola Politècnica Superior d'Alcoi | es_ES |
dc.description.bibliographicCitation | Bagan, J.; Martorell, M.; Cebrián, JL.; Rubert, A.; Bagán, L.; Mezquida, C.; Hervás-Marín, D. (2022). Effect of clinical and histologic features on time to malignancy in 224 cases of oral leukoplakia treated by surgery. Clinical Oral Investigations. 26(8):5181-5188. https://doi.org/10.1007/s00784-022-04486-x | es_ES |
dc.description.accrualMethod | S | es_ES |
dc.relation.publisherversion | https://doi.org/10.1007/s00784-022-04486-x | es_ES |
dc.description.upvformatpinicio | 5181 | es_ES |
dc.description.upvformatpfin | 5188 | es_ES |
dc.type.version | info:eu-repo/semantics/publishedVersion | es_ES |
dc.description.volume | 26 | es_ES |
dc.description.issue | 8 | es_ES |
dc.identifier.pmid | 35474554 | es_ES |
dc.identifier.pmcid | PMC9381619 | es_ES |
dc.relation.pasarela | S\470353 | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | es_ES |
dc.contributor.funder | European Regional Development Fund | es_ES |
dc.description.references | Warnakulasuriya S, Johnson NW, van der Waal I (2007) Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med 36(10):575–80. https://doi.org/10.1111/j.1600-0714.2007.00582.x | es_ES |
dc.description.references | Warnakulasuriya S, Kujan O, Aguirre-Urizar JM, Bagan JV, González-Moles MÁ, Kerr AR, Lodi G, Mello FW, Monteiro L, Ogden GR, Sloan P, Johnson NW (2021) Oral potentially malignant disorders: a consensus report from an international seminar on nomenclature and classification, convened by the WHO Collaborating Centre for Oral Cancer. Oral Dis 27(8):1862–1880. https://doi.org/10.1111/odi.13704 | es_ES |
dc.description.references | Holmstrup P, Vedtofte P, Reibel J, Stoltze K (2006) Long-term treatment outcome of oral premalignant lesions. Oral Oncol 42(5):461–74. https://doi.org/10.1016/j.oraloncology.2005.08.011 | es_ES |
dc.description.references | Warnakulasuriya S, Ariyawardana A (2016) Malignant transformation of oral leukoplakia: a systematic review of observational studies. J Oral Pathol Med 45(3):155–66. https://doi.org/10.1111/jop.12339 | es_ES |
dc.description.references | Aguirre-Urizar JM, Lafuente-Ibáñez de Mendoza I, Warnakulasuriya S (2021) Malignant transformation of oral leukoplakia systematic review and meta-analysis of the last 5 years. Oral Dis 27(8):1881–1895. https://doi.org/10.1111/odi.13810 | es_ES |
dc.description.references | Kuribayashi Y, Tsushima F, Morita KI, Matsumoto K, Sakurai J, Uesugi A, Sato K, Oda S, Sakamoto K, Harada H (2015) Long-term outcome of non-surgical treatment in patients with oral leukoplakia. Oral Oncol 51(11):1020–1025. https://doi.org/10.1016/j.oraloncology.2015.09.004 | es_ES |
dc.description.references | BarfiQasrdashti A, Habashi MS, Arasteh P, TorabiArdakani M, Abdoli Z, Eghbali SS (2017) Malignant transformation in leukoplakia and its associated factors in southern Iran: a hospital based experience. Iran J Public Health 46(8):1110–1117 | es_ES |
dc.description.references | Ibáñez Lafuente, de Mendoza I, Lorenzo Pouso AI, Aguirre Urízar JM, Barba Montero C, Blanco Carrión A, Gándara Vila P, Pérez Sayáns M (2022) Malignant development of proliferative verrucous multifocal leukoplakia a critical systematic review meta-analysis and proposal of diagnostic criteria. J Oral Pathol Med 51(1):30–38. https://doi.org/10.1111/jop.13246 | es_ES |
dc.description.references | Gandara-Vila P, Perez-Sayans M, Suarez-Penaranda JM, Gallas-Torreira M, Somoza-Martin J, Reboiras-Lopez MD, Blanco-Carrion A, Garcia-Garcia A (2018) Survival study of leukoplakia malignant transformation in a region of northern Spain. Med Oral Patol Oral Cir Bucal. 23(4):e413–e420. https://doi.org/10.4317/medoral.22326 | es_ES |
dc.description.references | Farah CS, Jessri M, Bennett NC, Dalley AJ, Shearston KD, Fox SA (2019) Exome sequencing of oral leukoplakia and oral squamous cell carcinoma implicates DNA damage repair gene defects in malignant transformation. Oral Oncol 96:42–50. https://doi.org/10.1016/j.oraloncology.2019.07.005 | es_ES |
dc.description.references | Li J, Liu Y, Zhang H, Hua H (2020) Association between hyperglycemia and the malignant transformation of oral leukoplakia in China. Oral Dis 26(7):1402–1413. https://doi.org/10.1111/odi.13372 | es_ES |
dc.description.references | Brouns E, Baart J, Karagozoglu Kh, Aartman I, Bloemena E, van der Waal I (2014) Malignant transformation of oral leukoplakia in a well-defined cohort of 144 patients. Oral Dis 20(3):e19-24. https://doi.org/10.1111/odi.12095 | es_ES |
dc.description.references | Chaturvedi AK, Udaltsova N, Engels EA, Katzel JA, Yanik EL, Katki HA, Lingen MW, Silverberg MJ (2020) Oral leukoplakia and risk of progression to oral cancer: a population-based cohort study. J Natl Cancer Inst 112(10):1047–1054. https://doi.org/10.1093/jnci/djz238 | es_ES |
dc.description.references | Wang T, Wang L, Yang H, Lu H, Zhang J, Li N, Guo CB (2019) Development and validation of nomogram for prediction of malignant transformation in oral leukoplakia: a large-scale cohort study. J Oral Pathol Med 48(6):491–498. https://doi.org/10.1111/jop.12862 | es_ES |
dc.description.references | Sundberg J, Öhman J, Korytowska M, Wallström M, Kjeller G, Andersson M, Horal P, Lindh M, Giglio D, Kovács A, Sand L, Hirsch JM, Magda Araújo Ferracini L, de Souza ACMF, Parlatescu I, Dobre M, Hinescu ME, Braz-Silva PH, Tovaru S, Hasséus B (2021) High-risk human papillomavirus in patients with oral leukoplakia and oral squamous cell carcinoma-a multi-centre study in Sweden Brazil and Romania. Oral Dis 27(2):183–192. https://doi.org/10.1111/odi.13510 | es_ES |
dc.description.references | Villa A, Woo SB (2017) Leukoplakia-a diagnostic and management algorithm. J Oral Maxillofac Surg 75(4):723–734. https://doi.org/10.1016/j.joms.2016.10.012 | es_ES |
dc.description.references | Odell E, Kujan O, Warnakulasuriya S, Sloan P (2021) Oral epithelial dysplasia: recognition, grading and clinical significance. Oral Dis 27(8):1947–1976. https://doi.org/10.1111/odi.13993 | es_ES |
dc.description.references | Lázaro E, Armero C, Gómez-Rubio V (2020) Approximate Bayesian inference for mixture cure models. TEST 29:750–767. https://doi.org/10.1007/s11749-019-00679-x | es_ES |
dc.description.references | Monteiro L, Barbieri C, Warnakulasuriya S, Martins M, Salazar F, Pacheco JJ, Vescovi P, Meleti M (2017) Type of surgical treatment and recurrence of oral leukoplakia: a retrospective clinical study. Med Oral Patol Oral Cir Bucal 22(5):e520–e526. https://doi.org/10.4317/medoral.21645 | es_ES |
dc.description.references | Tovaru S, Costache M, Perlea P, Caramida M, Totan C, Warnakulasuriya S, Parlatescu I (2022). Oral leukoplakia: a clinicopathological study and malignant transformation. Oral Dis. Jan 4. https://doi.org/10.1111/odi.14123. | es_ES |
dc.description.references | Schepman KP, van der Meij EH, Smeele LE, van der Waal I (1998) Malignant transformation of oral leukoplakia: a follow-up study of a hospital-based population of 166 patients with oral leukoplakia from The Netherlands. Oral Oncol 34(4):270–5 | es_ES |
dc.description.references | Warnakulasuriya S, Kovacevic T, Madden P, Coupland VH, Sperandio M, Odell E, Møller H (2011) Factors predicting malignant transformation in oral potentially malignant disorders among patients accrued over a 10-year period in South East England. J Oral Pathol Med. 40(9):677–83. https://doi.org/10.1111/j.1600-0714.2011.01054.x | es_ES |
dc.description.references | Napier SS, Cowan CG, Gregg TA, Stevenson M, Lamey PJ, Toner PG (2003) Potentially malignant oral lesions in Northern Ireland: size (extent) matters. Oral Dis 9(3):129–37. https://doi.org/10.1034/j.1601-0825.2003.02888.x | es_ES |